JCEM：青少年胰岛素增敏治疗可预防成年雄激素相当多的表型

EE-CA和PioFluMet放射治疗中会和放射治疗后CRP、CIMT、皮肉脂肪和MSI叠加

口服雌孕激素是少年荷尔蒙极少的准则放射治疗，即使当这些妈妈没有怀孕的后果。为了比较心血管疾病与抗生素增敏放射治疗介入非成年人少年儿童，在放射治疗中会和放射治疗后对荷尔蒙极少的制约，来自巴萨罗那大学Sant Joan de Deu医院内分泌科的Lourdes Ibanez客座教授及其制作组进行了一项研究课题，该研究课题辨认出少年儿童抗生素增敏放射治疗介入有可能持续性成年均荷尔蒙极少表DF。该研究课题结果在线发表在2012年4月1日的美国《临床内分泌代谢时尚杂志》（The journal of clinical endocrinology Price metabolism）上。该研究课题是一项随机非盲试验中，受试者是高抗生素血症和荷尔蒙极少的非成年人少年，且没有怀孕的后果（34例；岁数16岁；体重指数：23kg/m2）。研究课题比较炔雌醇醋酸环丙孕酮（EE-CA）与小剂量吡咯列酮（7.5mg/d）、氮他希伯来（62.5mg/d）和二甲双苯甲酸（850mg/d）联合（PioFluMet）放射治疗18个月的。放射治疗后随访6月。量度荷尔蒙极少（多毛症、痤疮分数和血清睾酮），刺激后抗生素，循环C反应蛋白，颈动脉增生中会层厚度，躯体组成（转化实测），臀部脂肪两区（磁共振成像）和性腺。该研究课题结果表明，EE-CA和PioFluMet同样缓解荷尔蒙极少，但有差异，以致制约其他结果。放射治疗后6个月，PioFluMet放射治疗的妈妈比EE-CA放射治疗的妈妈有不够较高的刺激后抗生素，不够较高的C反应蛋白高水平和不够薄的增生中会层，并且他们的皮肉脂肪较少，具有不够高的瘦体重，以及不够有可能有规律的性腺。该研究课题辨认出，在非成年人的荷尔蒙极少的少年儿童，PioFluMet放射治疗中会和放射治疗后的比心血管疾病的好。介入只能靠少年儿童荷尔蒙极少的增大制约放射治疗后的表DF。在少年儿童，PioFluMet相似的介入有可能持续性成年均荷尔蒙极少的表DF，除此以外成年人和生育能力大幅提高。与高血压相关的拓展阅读：

Diabetes Care：高血压与心衰病症脑部交感神经活性增大相关Diabetes Care：lixisenatide有效缓解二甲双苯甲酸控制不佳的2DF高血压人群的血糖2013 NIH 怀孕期高血压(GDM)诊断声明JAMA：褪黑激素分泌下降增加IIDF高血压后果DIABETES CARE：空腹血糖筛选怀孕高血压添新证Eur J Endocrinol: 1DF高血压病症HbA1c高水平过高能直接避免抑郁不够多数据请点击：有关高血压不够多资讯

Oral Contraception vs Insulin Sensitization for 18 Months in Nonobese Adolescents With Androgen Excess: Posttreatment Differences in C-Reactive Protein, Intima-Media Thickness, Visceral Adiposity, Insulin Sensitivity, and Menstrual Regularity BackgroundAn oral estro-progestagen is the standard medication given to adolescent girls with androgen excess, even when those girls are not at risk of pregnancy. AimThe aim of this study was to compare on-treatment and post-treatment effects of intervention with an oral contraceptive vs an insulin-sensitizing treatment for androgen excess in nonobese adolescents. DesignThis was a randomized, open-label trial. Study PopulationSubjects were nonobese adolescent girls with hyperinsulinemic androgen excess and without risk of pregnancy (mean age, 16 years; body mass index, 23 kg/m2; n = 34). InterventionsThe effects of treatment with ethinylestradiol-cyproteroneacetate (EE-CA) vs a low-dose combination of pioglitazone (7.5 mg/d), flutamide (62.5 mg/d), and metformin (850 mg/d) (PioFluMet) for 18 months were studied. Posttreatment follow-up was for 6 months. Main Outcome MeasuresAndrogen excess (hirsutism and acne scores and serum testosterone), glucose-stimulated insulinemia, circulating C-reactive protein, carotid intima media thickness, body composition (absorptiometry), abdominal fat partitioning (magnetic resonance imaging), and menstrual regularity were measured. ResultsEE-CA and PioFluMet attenuated androgen excess similarly but had divergent, and even opposing, effects on other outcomes. Six months posttreatment, the PioFluMet-treated girls had a lower glucose-induced insulinemia, a lower C-reactive protein level, and a thinner intima media than the EE-CA–treated girls, and they were viscerally less adipose, had a higher lean mass, and were more likely to he regular cycles. ConclusionsThe on-treatment and post-treatment effects of PioFluMet compared forably with those of oral contraception in nonobese adolescents with androgen excess. The intervention whereby androgen excess is reduced in adolescence influences the post-treatment phenotype. PioFluMet-like interventions in adolescence may thus hold the potential to prevent part of the androgen-excess phenotype in hood, including adiposity and subfertility.